Monitoring Neural Tissues Properties by Modulated Imaging (MI)

Sponsor
University of California, Irvine (Other)
Overall Status
Withdrawn
CT.gov ID
NCT00555711
Collaborator
Beckman Laser Institute University of California Irvine (Other)
0
2
38
0
0

Study Details

Study Description

Brief Summary

We have developed a safe, non-contact, intra-operative guidance system to optimize tumor resection in neurosurgery. The Modulated Imaging is non-contact optical imaging technology developed at the Beckman Laser Institute, UCI.

Compared to other imaging approaches, MI has the unique capability of performing both diffuse optical tomography and rapid, wide-field quantitative mapping of tissue optical properties within a single measurement platform.

Preliminary in vivo studies have shown that brain tumors, infiltrating tumor margins and normal brain may have intrinsically different optical properties.

Condition or Disease Intervention/Treatment Phase
  • Device: Modulated Imaging

Detailed Description

While compatible with time-modulation methods, MI alternatively uses spatially-modulated illumination for imaging of tissue constituents.

The Modulated Imaging system consists of

  1. a light projection system that illuminates the tissue with spatial sinusoid patterns.

  2. a CCD camera which collects the diffusely reflected light in a non-contact geometry. The wavelength of illumination can be selected by bandpass filtering of a broadband source,or by use of a monochromatic source.

Lastly, tissue fluorescence measurements can be performed by placing a combination of source-blocking and bandpass emission filters in front of the camera.

The diffusely reflected amplitude of the modulated wave carries both optical property (absorption, fluorescence, scattering) and depth information. Specifically, the sampling depth of the spatially-modulated wave is a function of the frequency of illumination and the tissue optical properties.

During neurosurgery when nervous tissue is exposed by the attending neurosurgeon, intraoperative pictures will be taken using the modulated imager by the investigators.

The imaging procedure may delay completion of the surgical case by an estimated 10 to 20 minutes. This is minimal prolongation considering most brain tumor resections take several hours.

The images acquired will be processed after the surgical procedure and will not be available to the surgeon during the operative procedure.

Study Design

Study Type:
Observational
Actual Enrollment :
0 participants
Observational Model:
Case-Only
Time Perspective:
Cross-Sectional
Official Title:
Monitoring Neural Tissues Properties by Modulated Imaging (MI)
Study Start Date :
Nov 1, 2008
Anticipated Primary Completion Date :
Jan 1, 2012
Anticipated Study Completion Date :
Jan 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Modulated Imaging

Modulated Imaging

Device: Modulated Imaging
Modulated Imaging

Outcome Measures

Primary Outcome Measures

  1. Brain Tissue Property [12 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Minute and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • All nervous system tumor patients who undergo a preoperative MRI,and undergoing central nervous system operative procedures for non tumor.
Exclusion Criteria:
  • All emergency neurosurgical procedures.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Beckman Laser Institute,University of California,Irvine Irvine California United States 92612
2 Neurosurgery department,University of California,Irvine Orange California United States 92868

Sponsors and Collaborators

  • University of California, Irvine
  • Beckman Laser Institute University of California Irvine

Investigators

  • Principal Investigator: Mark Linskey, MD, University of California, Irvine
  • Principal Investigator: Bruce J Tromberg, PhD, Beckman Laser Institute University of California Irvine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Beckman Laser Institute and Medical Center, Mark Linskey, MD.,Department of Neurosurgery, University of California, Irvine
ClinicalTrials.gov Identifier:
NCT00555711
Other Study ID Numbers:
  • NIH-LAMMP 2005-4775
First Posted:
Nov 9, 2007
Last Update Posted:
Feb 10, 2017
Last Verified:
Feb 1, 2017
Keywords provided by Beckman Laser Institute and Medical Center, Mark Linskey, MD.,Department of Neurosurgery, University of California, Irvine
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 10, 2017